Nanoplatforms for delivery of siRNA to the eye

Current Pharmaceutical Design

Volumn 21, Issue 31, 2015, Pages 4587-4593

  Kataki, Manjir Sarma ^a   Kakoti, Bibhuti Bhusan ^a   Jameson, Melanie ^b   Solanki, Aum ^b   Hirani, Anjali ^b   Pathak, Yashwant ^b  

^a DIBRUGARH UNIVERSITY   (India)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Dendrimers; Drug delivery; Lipid nanoparticles; Nanoplatforms; Ocular; Polymers; Proteins; SiRNA

Indexed keywords

DENDRIMER; LIPID; NANOCARRIER; NANOMATERIAL; NANOPARTICLE; PROTEIN; SMALL INTERFERING RNA;

AGE RELATED MACULAR DEGENERATION; ANTERIOR EYE SEGMENT; DRUG DELIVERY SYSTEM; EYE DISEASE; GENE TARGETING; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; NONHUMAN; POLYMERIZATION; POSTERIOR EYE SEGMENT; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TARGET ORGAN; ANIMAL; BIOAVAILABILITY; EYE DISEASES; GENETICS; TISSUE DISTRIBUTION;

ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; EYE DISEASES; HUMANS; NANOPARTICLES; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION;

EID: 84946781277     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282131151013191051     Document Type: Review

References (61)

1. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006; 58: 1131-1135.
2. Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm 2002; 28: 473-493.
3. Hämäläinen KM, Kananen K, Auriola S, Kontturi K, Urtti A. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci 1997; 38: 627-634.
4. Keister JC, Cooper ER, Missel PJ, Lang JC, Hager DF. Limits on optimizing ocular drug delivery. J Pharm Sci 1991; 80: 50-53.
5. Schoenwald RD. Ocular drug delivery: pharmacokinetics considerations. Clin Pharmacokinet 1990; 18: 255-269.
6. Sasaki H, Yamamura K, Mukai T, et al. Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst 1999; 16: 85-146.
7. Edwards A, Prausnitz MR. Predicted permeability of the corneal to topical drugs. Pharm Res 2001; 18: 1497-1508.
8. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blooderetina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 2006; 58: 1136-1163.
9. Amo EMd, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 2008; 13: 135-143.
10. Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther 2003; 3: 45-56.
11. Tekmira Pharmaceuticals Corporation - Leader in the Development of RNAi Therapeutic Agents. http://www.ic.gc.ca/app/ccc/srch/nvgt.do?lang=eng&prtl=1&sbPrtl =&estblmntNo=123456161461&profile=cmpltPrfl&profileId=201 &app=sold.
12. Thakur A, Fitzpatrick S, Zaman A, et al. Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers. J Biol Eng 2012; 6: 7.
13. Fougerolles Ad, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007; 6: 443-453.
14. Reischl D, Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomed Nanotechnol Biol Med 2009; 5: 8-20.
15. Watts JK, Deleavey GF, Damha MJ. Chemically modified siRNA: tools and applications. Drug Discov Today 2008; 13: 842-55.
16. Couto L, High K. Viral vector-mediated RNA interference. Curr Opin Pharmacol 2010; 10: 534-542.
17. Grayson A, Doody A, Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res 2006; 23: 1868-1876.
18. Kim B, Tang Q, Biswas P, et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol 2004; 165: 2177-2185.
19. Günther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm 2011; 77: 438-449.
20. Duan Y, Guan X, Ge J, et al. Cationic nanocopolymers mediated IKKbeta targeting siRNA inhibit the proliferation of human Te- non's capsule fibroblasts in vitro. Mol Vis 2008; 14: 2616-2628.
21. Ye H, Qian Y, Lin M, et al. Cationic nano-copolymers mediated IKK targeting siRNA to modulate wound healing in a monkey model of glaucoma filtration surgery. Mol Vis 2010; 16: 2502-2510.
22. Soriano P, Dijkstra J, Legrand A, et al. Targeted and nontargeted liposomes for in vivo transfer to rat liver cells of a plasmid containing the preproinsulin I gene. Proc Natl Acad Sci USA 1983; 80: 7128-7131.
23. Liu H, Liu Y, Ma Z, Wang J, Zhang Q. A Lipid Nanoparticle System Improves siRNA Efficacy in RPE Cells and a Laser-Induced Murine CNV Model. Invest Ophthalmol Vis Sci 2011; 52: 4789-4794.
24. Lochmann D, Weyermann J, Georgens C, Prassl R, Zimmer A. Albuminprotamine-oligonucleotide nanoparticles as a new an- tisense delivery system. Part 1: Physicochemical characterization. Eur J Pharm Biopharm 2005; 59: 419-429.
25. Johnson L, Cashman S, Kumar-Singh R. Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea. Mol Ther 2008; 16: 107-114.
26. Laufer S, Restle T. Peptide-mediated cellular delivery of oligonu-cleotide-based therapeutics in vitro: quantitative evaluation of Nanoplatforms for Delivery of siRNA to the Eye overall efficacy employing easy to handle reporter systems. Curr Pharm Des 2008; 14: 3637-3655.
27. Khar R, Jain G, Warsi M, et al. Nanovectors for the ocular delivery of nucleic acid-based therapeutics. Indian J Pharm Sci 2010; 72: 675-688.
28. Marano R, Wimmer N, Kearns P, et al. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp Eye Res 2004; 79: 525-535.
29. Marano R, Toth I, Wimmer N, Brankov M, Rakoczy P. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 2005; 12: 1544-1550.
30. Agrawal A, Min D, Singh N, Zhu H, Bhatia S. Functional delivery of siRNA in mice using dendriworms. ACS Nano 2009; 3: 2495-2504.
31. Han L, Zhang A, Wang H, et al. Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Hum Gene Ther 2010; 21: 417-426.
32. Kaiser PK, Symons RA, Shah SM, et al. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol 2010; 150(1): 33-39.
33. Allergan A. Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration. In: ClinicalTrials.gov. 2011. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00395057 of the record NLM Identifier: NCT00395057.
34. Kaiser P, Symons R, Shah S, Quinlan E, Nguyen Q. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol 2010; 150: 33-39.
35. OPKO Health, Inc. Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CO- BALT). In: ClinicalTrials.gov. 2014. Available from: https://clinicaltrials.gov/ct2/show/NCT00499590 of the record NLM Identifier: NCT00499590.
36. Quark Pharmaceuticals; Pfizer. Phase II Open Label Multicenter, Prospective, Randomized, Age Related Macular Degeneration, Comparator Controlled Study Evaluating PF-04523655 Versus Ranibizumab In The Treatment Of Subjects With Choroidal Neovascularization (MONET Study). In: ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00713518 of the re- cord NLM Identifier: NCT00713518.
37. Quark PF-655 Development Pipeline: http://quarkpharma.com/?page_id=28.
38. Tiemann K, Rossi J. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med 2009; 1: 142-151.
39. Pfizer. Prospective, Randomized, Multi-Center, Comparator Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema (DEGAS). In: ClinicalTri- als.gov. 2008. NCT00701181.
40. Quark Pharmaceuticals. Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients. In: ClinicalTrials.gov. 2013. Available from: https://clinicaltrials.gov/ct2/show/NCT01064505 of the record NLM Identifier: NCT01064505.
41. Sylentis, S.A. Tolerance and Effect on Intraocular Pressure After Administration of SYL040012. In: ClinicalTrials.gov. 2010. Available from: https://clinicaltrials.gov/ct2/show/NCT00990743 of the record NLM Identifier: NCT00990743.
42. Guzman-Aranguez A, Loma P, Pintor J. Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy. Br J Pharmacol 2013; 170: 730-747.
43. Ramachandran PV, Ignacimuthu S. RNA interference--a silent but an efficient therapeutic tool. Appl Biochem Biotechnol 2013; 169: 1774-1789.
44. Varma R, Lee PP, Goldberg I, Kotak S. An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol 2011; 152: 515-522.
45. Maylahn C, Gohdes DM, Balamurugan A, Larsen BA. Age-related eye diseases: an emerging challenge for public health professionals. Prevent Chronic Dis 2005; 2: A17.
46. Mahdy MA-MS. Gene therapy in glaucoma-3: Therapeutic approaches. Oman J Ophthalmol 2010; 3: 109-116.
47. Pañeda C, Jimenez AI, Wright N, Martínez T. Recent Advances in Ocular Nucleic Acid-Based Therapies: The Silent Era. USA: IN- TECH Open Access Publisher 2010.
48. Campochiaro PA. Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther 2006; 13: 559-562.
49. Turchinovich A, Zoidl G, Dermietzel R. Non-viral siRNA delivery into the mouse retina in vivo. BMC Ophthalmol 2010; 10: 25.
50. Aggarwal P, Hall J, McLeland C, Dobrovolskaia A, McNeil S. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009; 61: 428-437.
51. Gref R, Minamitake Y, Peracchia M, Trubetskoy V, Torchilin V, R RL. Biodegradable long-circulating polymeric nanospheres. Sci- ence 1994; 263: 1600-1603.
52. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target independent angiogenesis suppression by siRNA via TLR3. Nature 2008; 452: 591-597.
53. Wong C, Stylianopoulos T, Cui J, Martin J, Fukumura D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. PNAS 2011; 108: 2426-2431.
54. Gratton S, Ropp P, Pohlhaus P, et al. The effect of particle design on cellular internalization pathways. PNAS 2008; 105: 11613-11618.
55. Petros R, DeSimone J. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010; 9: 615-627.
56. Yokoe J, Sakuragi S, Yamamoto K, et al. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. Int J Pharm 2008; 353: 28-34.
57. Furumoto K, Yokoe J, Ogawara K, et al. Effect of coupling of albumin onto surface of PEG liposome on its in vivo disposition. Int J Pharm 2007; 329: 110-116.
58. Davis M, Zuckerman J, Choi C, Seligson D, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067-1070.
59. Breitbach C, Burke J, Jonker D, Stephenson J, Haas A, Kirn D. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477: 99-102.
60. Hu Y, Atukorale P, Lu J, et al. Cytosolic delivery mediated via electrostatic surface binding of protein, virus, or siRNA cargos to pH-responsive core-shell gel particles. Biomacromolecules 2009; 10: 756-765.
61. You J, Almeda D, Ye G, Auguste D. Bioresponsive matrices in drug delivery. J Biol Eng 2010; 4.